Reports
Remdesivir Less Expensive for "Government Programs"? Not So Fast.
Two options are proposed if Gilead wishes to offer the discounts to the full array of government programs.
Download Report
Originally published
on 07/01/2020
Drug Pricing Lab
Remdesivir is an investigational antiviral drug that recently gained prominence as the only drug authorized for emergency use against COVID-19. On Monday, Gilead revealed its pricing plans in the U.S., charging hospitals $3,120 for a typical patient.
Additionally, Dan O'Day, the CEO of Gilead, promised on CNBC and in an open letter that Remdesivir would have a lower 'government price' in the U.S. for a five-day course. However, the discount will only apply to a select group of smaller government programs, excluding Medicare and Medicaid. Dr. Bach proposes two options if Gilead wishes to discount Remdesivir to the full array of government programs.
Share